

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM839720

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
CLINIGEN LIMITED		08/10/2023	Private Limited Company: UNITED KINGDOM
RECEIVING PARTY DATA			
Name:	CNX Therapeutics Limited		
Street Address:	3 Bunhill Row		
City:	London		
State/Country:	UNITED KINGDOM		
Postal Code:	EC1Y 8YZ		
Entity Type:	Private Limited Company: UNITED KINGDOM		
PROPERTY NUMBERS Total: 2			
Property Type	Number	Word Mark	
Registration Number:	3399644	TOTECT	
Registration Number:	1618361	ETHYOL	
CORRESPONDENCE DATA			
Fax Number:	6124927077		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	612-492-7000		
Email:	plarson@fredlaw.com		
Correspondent Name:	Patricia Larson, Sr. Trademark Paralegal		
Address Line 1:	Fredrikson & Byron, P.A.		
Address Line 2:	60 South Sixth Street, Suite 1500		
Address Line 4:	Minneapolis, MINNESOTA 55402		
NAME OF SUBMITTER:	Patricia A. Larson		
SIGNATURE:	/Patricia A. Larson/		
DATE SIGNED:	09/15/2023		
Total Attachments: 34			
source=IP Agreement Clinigen Limited#page1.tif			
source=IP Agreement Clinigen Limited#page2.tif			
source=IP Agreement Clinigen Limited#page3.tif			

OP \$65.00 3399644

source=IP Agreement Clinigen Limited#page4.tif
source=IP Agreement Clinigen Limited#page5.tif
source=IP Agreement Clinigen Limited#page6.tif
source=IP Agreement Clinigen Limited#page7.tif
source=IP Agreement Clinigen Limited#page8.tif
source=IP Agreement Clinigen Limited#page9.tif
source=IP Agreement Clinigen Limited#page10.tif
source=IP Agreement Clinigen Limited#page11.tif
source=IP Agreement Clinigen Limited#page12.tif
source=IP Agreement Clinigen Limited#page13.tif
source=IP Agreement Clinigen Limited#page14.tif
source=IP Agreement Clinigen Limited#page15.tif
source=IP Agreement Clinigen Limited#page16.tif
source=IP Agreement Clinigen Limited#page17.tif
source=IP Agreement Clinigen Limited#page18.tif
source=IP Agreement Clinigen Limited#page19.tif
source=IP Agreement Clinigen Limited#page20.tif
source=IP Agreement Clinigen Limited#page21.tif
source=IP Agreement Clinigen Limited#page22.tif
source=IP Agreement Clinigen Limited#page23.tif
source=IP Agreement Clinigen Limited#page24.tif
source=IP Agreement Clinigen Limited#page25.tif
source=IP Agreement Clinigen Limited#page26.tif
source=IP Agreement Clinigen Limited#page27.tif
source=IP Agreement Clinigen Limited#page28.tif
source=IP Agreement Clinigen Limited#page29.tif
source=IP Agreement Clinigen Limited#page30.tif
source=IP Agreement Clinigen Limited#page31.tif
source=IP Agreement Clinigen Limited#page32.tif
source=IP Agreement Clinigen Limited#page33.tif
source=IP Agreement Clinigen Limited#page34.tif

Dated 10 August 2023

Intellectual Property Rights Assignment and Domain Names Transfer Deed

between

Clinigen Limited
as Assignor

and

CNX Therapeutics Limited
as Assignee

White & Case LLP
5 Old Broad Street
London EC2N 1DW

TRADEMARK
REEL: 008204 FRAME: 0476

This Deed is made on 10 August 2023

Between:

Parties

- (1) **Clinigen Limited**, a limited liability company established under the laws of England and Wales, with registered number 06771928 and whose registered office is at Pitcairn House Crown Square, Centrum 100, Burton On Trent, Staffordshire, DE14 2WW, United Kingdom (the “Assignor”); and
- (2) **CNX Therapeutics Limited**, a company incorporated in England and Wales with registered number 03363032 and whose registered office is at 3 Bunhill Row, London, EC1Y 8YZ, United Kingdom (the “Assignee”).

Whereas:

- (A) On the date of this Deed, the Assignor and Clinigen Healthcare Limited (together, the “Sellers”) and the Assignee (as purchaser) entered into an Asset Sale and Purchase Agreement, for the sale by the Sellers, and the purchase by the Assignee, of the Business Assets (as defined below) (the “Asset Sale and Purchase Agreement”).
- (B) The Business Assets include the CL Business Intellectual Property Rights (as defined below).
- (C) Pursuant to the terms of the Asset Sale and Purchase Agreement, the Assignor has agreed to assign all of the Assignor’s right, title and interest in and with respect to the CL Business Intellectual Property Rights, and to transfer the registration of the Business Domain Names (as defined below) comprised in the CL Business Intellectual Property Rights, to the Assignee, and the Assignee has agreed to accept such assignment and transfer, on the terms and subject to the conditions of this Deed.
- (D) It is the intention of the Parties that this document be executed as a deed.

Pursuant to, and for the consideration set out in, the Asset Sale and Purchase Agreement, and for and in consideration of the mutual promises and obligations set out in this Deed, **it is agreed:**

1. Definitions and Interpretation

1.1 In this Deed the following expressions have the following meanings:

“**Agents**” means, in relation to a person, that person’s directors, officers, employees, advisers, agents and representatives;

“**Artwork**” means any and all artwork (including Product logos and artwork on packaging) that relates exclusively to any of the Products and has been used exclusively in the operation or conduct of the Business in the three (3) years before the date of the Asset Sale and Purchase Agreement;

“**Asset Sale and Purchase Agreement**” has the meaning given to it in Recital (A);

“**Business Assets**” has the meaning given to it in the Asset Sale and Purchase Agreement;

“**Business Day**” means a day (other than a Saturday or Sunday or a public holiday) when commercial banks are open for ordinary banking business in London, England;

“**Business Domain Names**” means the domain names set forth in **Schedule 3** (*Domain Names*);

“**Business Patents**” means the patents set forth in **Schedule 2** (*Patents*);

“**CL Business Copyrights and Design Rights**” means any copyrights and design rights that (a) are, at the date of this Agreement, owned by the Assignor and (b) subsist in any Artwork;

“**CL Business Intellectual Property Rights**” means:

- (a) the CL Business Trade Marks;
- (b) the Business Patents;
- (c) the CL Business Copyrights and Design Rights; and
- (d) the Business Domain Names;

“**CL Business Trade Marks**” means the registered trade marks set forth in Schedule 1 (*Registered Trade Marks*);

“**Group**” has the meaning given to it in the Asset Sale and Purchase Agreement;

“**Party**” means a party to this Deed and “**Parties**” means the parties to this Deed;

“**Products**” has the meaning given to it in the Asset Sale and Purchase Agreement;

“**Related Person**” has the meaning given in Clause 6.5;

“**Relevant Party’s Group**” means, in relation to a Party, that Party’s Group;

“**Sellers**” has the meaning given to it in Recital (A); and

“**Transaction Documents**” has the meaning given to it in the Asset Sale and Purchase Agreement.

- 1.2 Any reference to “**writing**” or “**written**” means any method of reproducing words in a legible and non-transitory form (excluding, for the avoidance of doubt, email).
- 1.3 References to “**include**” or “**including**” are to be construed without limitation.
- 1.4 References to a “**company**” include any company, corporation or other body corporate wherever and however incorporated or established.
- 1.5 References to a “**person**” include any individual, company, partnership, joint venture, firm, association, trust, governmental or regulatory authority or other body or entity (whether or not having separate legal personality).
- 1.6 The expressions “**body corporate**”, “**holding company**”, “**parent undertaking**”, “**subsidiary**” and “**subsidiary undertaking**” shall have the meaning given in the Companies Act.
- 1.7 The table of contents and headings are inserted for convenience only and do not affect the construction of this Deed.
- 1.8 Unless the context otherwise requires, words in the singular include the plural and vice versa and a reference to any gender includes all other genders.
- 1.9 References to Clauses, paragraphs and Schedules are to clauses and paragraphs of, and schedules to, this Deed. The Schedules form part of this Deed.
- 1.10 A person shall be deemed to be affiliated with another if such person is connected with the other within the meaning of s.1122 of the Corporation Tax Act 2010.
- 1.11 References to any statute or statutory provision include a reference to that statute or statutory provision as amended, consolidated or replaced from time to time (whether before or after the

date of this Deed) and include any subordinate legislation made under the relevant statute or statutory provision except to the extent that any amendment, consolidation or replacement would increase or extend the liability of the Assignor under this Deed.

- 1.12 References to any English legal term for any action, remedy, method of financial proceedings, legal document, legal status, court, official or any legal concept or thing shall, in respect of any jurisdiction other than England, be deemed to include what most nearly approximates in that jurisdiction to the English legal term.
- 1.13 This Deed shall be binding on and be for the benefit of the successors of the Parties.

2. Assignment and Transfer

- 2.1 The Assignor hereby absolutely and irrevocably assigns to the Assignee, and the Assignee hereby accepts the assignment of, all of the Assignor's right, title and interest in and with respect to the CL Business Intellectual Property Rights, together with the goodwill of the business to the extent relating to the goods or services with respect to which the CL Business Trade Marks have been registered or used, and including all statutory and common law rights attaching to the CL Business Trade Marks, the Business Patents and the CL Business Copyrights and Design Rights and any and all rights arising from ownership of the CL Business Trade Marks, the Business Patents and the CL Business Copyrights and Design Rights, including all rights to bring, make, oppose, defend and appeal proceedings, claims or actions with respect to any of the foregoing and obtain relief (and to recover and retain any damages or accounts of profits) in respect of any infringement, dilution, misappropriation, violation, or misuse, or any other cause of action (including passing off) arising from ownership, of any of the CL Business Trade Marks, the Business Patents and the CL Business Copyrights and Design Rights, whether occurring before, on, or after the date of this Deed.
- 2.2 The Assignor shall transfer, and hereby absolutely and irrevocably transfers, to the Assignee, and the Assignee shall accept, and hereby accepts, the transfer of, the registration of the Business Domain Names and all rights with respect to such Business Domain Names.
- 2.3 The Assignor shall promptly after the execution of this Deed and at the Assignee's expense complete all steps and formalities as are necessary to complete the transfer of the registration and full control of the Business Domain Names to the Assignee and to register the Assignee as the registrant of the Business Domain Names.

3. Recordal of the Assignments

Except to the extent prohibited or required otherwise by applicable law, and subject to Clause 2.3 and Clause 4, (a) the Assignee shall be solely responsible, at its own cost and expense, for all recordals of the assignments of the CL Business Trade Marks and the Business Patents made under this Deed, including all filings and other actions required to make such recordals, and all costs and expenses incurred in connection therewith, including filing and local counsel fees, and (b) the Assignor shall, at the Assignee's written request and expense, do, execute and deliver (or procure to be done, executed and delivered) all such further acts, documents and things reasonably required by the Assignee in order to assist the Assignee with the recordal of the assignments of the CL Business Trade Marks and the Business Patents made under this Deed.

4. Further Assurance

Without prejudice to the terms of the Asset Sale and Purchase Agreement, and except as set forth otherwise in (a) Clause 2.3 with respect to the transfer of the registration and full control of the Business Domain Names and with respect to the registration of the Assignee as the

registrant of the Business Domain Names under this Deed and (b) Clause 3 with respect to the recordal of the assignments of the CL Business Trade Marks and the Business Patents under this Deed, the Assignor and the Assignee respectively shall from time to time and at their own cost do, execute and deliver or procure to be done, executed and delivered all such further acts, documents, information and things required by law or otherwise, and in a form satisfactory to the other, in order to give full effect to this Deed.

5. Representations and Warranties

Without prejudice to the express warranties, representations and conditions in the Asset Sale and Purchase Agreement with respect to the CL Business Intellectual Property Rights, all warranties, representations or conditions implied by statute or at common law, on the basis of usage, custom or the Parties' previous course of dealings, in fact or otherwise, are hereby excluded to the fullest extent permitted by applicable law.

6. Entire Agreement

- 6.1 This Deed, together with the other Transaction Documents, constitutes the whole agreement between the Parties and supersede any previous arrangements or agreements between them relating to the sale, purchase and assignment of the CL Business Intellectual Property Rights and the transfer of the Business Domain Names.
- 6.2 The Parties acknowledge that any warranties and representations in relation to the CL Business Intellectual Property Rights are set out in the Asset Sale and Purchase Agreement. Without prejudice to any other rights or remedies that each Party may have under the other Transaction Documents, each Party confirms that it has not entered into this Deed on the basis of any representation, warranty, undertaking or other statement whatsoever by the other Party or any of the Related Persons of the other Party which is not expressly incorporated into this Deed and that, to the extent permitted by law, a Party shall have no right or remedy in relation to action taken in connection with this Deed other than pursuant to this Deed and each Party waives all and any other rights or remedies.
- 6.3 Without prejudice to any other rights or remedies that a Party may have under the other Transaction Documents, a Party's only right or remedy in respect of any provision of this Deed shall be for breach of this Deed, and no party shall have any right or remedy under or in connection with this Deed in respect of misrepresentation (whether negligent or innocent and whether made before or in this Deed) and each Party waives all and any rights or remedies under or in connection with this Deed in respect of misrepresentation which it may have in relation to any matter to the fullest extent permitted by law.
- 6.4 Save for any claim under or for breach of this Deed or any claim made in accordance with the terms of the other Transaction Documents, no Party nor any of its Related Persons shall have any right or remedy, or make any claim, against the other Party nor any of its Related Persons in connection with the sale, purchase and assignment of the Assignor's right, title and interest in and with respect to the CL Business Intellectual Property Rights and the transfer of the Business Domain Names.
- 6.5 In this Clause 6, "**Related Persons**" means, in relation to a Party, members of the Relevant Party's Group and the Agents of that Party and of members of the Relevant Party's Group.
- 6.6 Nothing in this Clause 6 shall operate to limit or exclude any liability for fraud.

7. Severance and Validity

If any provision of this Deed is or becomes illegal, invalid or unenforceable in any respect under the law of any jurisdiction, it shall be deemed to be severed from this Deed. The remaining provisions will remain in full force in that jurisdiction and all provisions will continue in full force in any other jurisdiction.

8. Variations

No variation or restatement of this Deed shall be effective unless in writing and signed by or on behalf of each of the Parties.

9. Remedies and Waivers

- 9.1 No waiver of any right under this Deed shall be effective unless in writing. Unless expressly stated otherwise a waiver shall be effective only in the circumstances for which it is given.
- 9.2 No delay or omission by any Party in exercising any right or remedy provided by law or under this Deed shall constitute a waiver of such right or remedy.
- 9.3 The single or partial exercise of a right or remedy under this Deed shall not preclude any other nor restrict any further exercise of any such right or remedy.
- 9.4 The rights and remedies provided in this Deed are cumulative and do not exclude any rights or remedies provided by law except as otherwise expressly provided.

10. Third Party Rights

- 10.1 Save as expressly provided in Clause 10.2, a person who is not a Party or its successor or permitted assignee shall have no right under the Contracts (Rights of Third Parties) Act 1999 to enforce any of the terms of this Deed.
- 10.2 Clause 6 (*Entire Agreement*) is intended to benefit a Party's Related Persons, and each such Clause shall be enforceable by any of them under the Contracts (Rights of Third Parties) Act 1999, subject to the other terms and conditions of this Deed.
- 10.3 The Parties may amend or vary this Deed in accordance with its terms without the consent of any other person.

11. Costs and Expenses

Except as provided otherwise, each Party shall pay its own costs and expenses in connection with the negotiation, preparation and performance of this Deed.

12. Notices

- 12.1 Any notice or other communication in connection with this Deed (each, a "Notice") shall be:
 - (a) in writing;
 - (b) in English; and
 - (c) delivered by hand, pre-paid recorded delivery, pre-paid special delivery or courier using an internationally recognized courier company, or email.

- 12.2 A Notice shall be effective upon receipt and shall be deemed to have been received:
- (a) 9.00 am on the second Business Day after posting, if sent by pre-paid post, or at the time recorded by the delivery service if sent by recorded delivery;
 - (b) at the time of delivery, if delivered by hand or courier; or
 - (c) at time of sending, if sent by email, except that receipt shall not occur if the sender receives an automated message indicating that the message has not been delivered to the recipient,

provided that if deemed receipt of any Notice occurs after 6.00 pm or is not on a Business Day, deemed receipt of the Notice shall be 9.00 am on the next Business Day. References to time in this Clause 12.2 are to local time in the country of the addressee.

12.3 The addresses for service of Notice are:

(a) Assignor:

Name: Clinigen Limited
Address: Pitcairn House Crown Square, Centrum 100
Burton On Trent
Staffordshire
DE14 2WW
United Kingdom
Attention: Head of Legal
Email: legalandcontracts@clinigengroup.com;

with a copy (which shall not constitute Notice) to:

Name: White & Case LLP
Address: 5 Old Broad Street
London
EC2N 1DW
United Kingdom
Attention: Lucy Bullock, Michael Weir and Ben von Maur
Email: lucy.bullock@whitecase.com;
mike.weir@whitecase.com;
ben.vonmaur@whitecase.com; and

(b) Assignee:

Name: CNX Therapeutics Limited
Address: LABS House
15-19 Bloomsbury Way
London
WC1A 2TH
United Kingdom
Attention: Sarah Morbey, Ben Moore, Guy Clarke
Email: sarah.morbey@cnx-therapeutics.com;
ben.moore@cnx-therapeutics.com;
guy.clark@cnx-therapeutics.com;

with a copy (which shall not constitute Notice) to:

Name: Trowers and Hamlins LLP
Address: 3 Bunhill Row
London
EC1Y 8YZ
United Kingdom
Attention: Mark Churchman, Rachael Hershman, Adrian Moss
Email: mchurchman@trowers.com;
rhershman@trowers.com
amos@trowers.com;

- 12.4 A Party shall notify the other Party of any change to its details in Clause 12.3 in accordance with the provisions of this Clause 12, provided that such notification shall only be effective on the later of the date specified in the notification and five (5) Business Days after deemed receipt.

13. Counterparts

This Deed may be executed in counterparts and shall be effective when each Party has executed and delivered a counterpart. Each counterpart shall constitute an original of this Deed, but all the counterparts shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page of this Deed by electronic imaging means shall be effective as delivery of a manually executed counterpart of this Deed.

14. Governing Law and Jurisdiction

- 14.1 This Deed and any dispute, claim or non-contractual obligations arising out of or in connection with this Deed is governed by and shall be construed in accordance with English law.
- 14.2 The Parties agree that the courts of England shall have exclusive jurisdiction to hear and determine any suit, action or proceedings arising out of or in connection with this Deed (including any non-contractual obligations arising out of or in connection with this Deed) and, for such purposes, irrevocably submit to the jurisdiction of such courts.

This document has been executed as a deed and is delivered and takes effect on the date first above written.

Schedule 1 Registered Trade Marks

Part 1 CARDIOXANE

No	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
1.	Cardioxane	Albania	05	Registered	AL/T/2003/000001	06-Jan-2003	9743	23-Feb-2004	6-Jan-2033
2.	Cardioxane	Argentina	05	Registered	3598373	25-Apr-2017	2920347	15-Dec-2017	21-Jun-2027
3.	Cardioxane	Australia	05	Registered	741817	19-Aug-1997	741817	24-Apr-1998	19-Aug-2027
4.	Cardioxane	Azerbaijan	05	Registered		04-May-2010	20110720	7-Jul-2011	04-May-2030
5.	Cardioxane	Belarus	05	Registered	20011103	17-May-2001	17765	12-Sep-2003	17-May-2031

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
6.	Cardioxane	Bolivia	05	Registered		21-Jun-1995	95690-A	21-Jun-1995	21-Jun-2025
7.	Cardioxane	Bosnia & Herzegovina	05	Registered	BAR1997972283	27-May-1997	972283	8-Feb-2002	24-Sep-2030
8.	Cardioxane	Brazil	05	Registered	817315195	18-Jun-1993	817315195	20-Dec-1994	20-Dec-2024
9.	Cardioxane	Chile	01,05	Registered	1200983	21-Apr-2016	1208040	11-Jun-2016	28-Jun-2026
10.	Cardioxane	Colombia	05	Registered	98008399	17-Feb-1998	228734	27-Jan-2001	27-Jan-2030
11.	Cardioxane	Colombia	05	Registered	08052206	22-May-2008	374563	12-Mar-2009	12-Mar-2029

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
12.	Cardioxane	Croatia	05	Registered	Z931967A	08-Jun-1993	Z931967	24-May-1996	24-Sep-2030
13.	Cardioxane	Dominican Republic	05	Registered		15-Jul-1995	79089	15-Jul-1995	15-Jul-2025
14.	Cardioxane	Ecuador	05	Registered			1-4299-2009	29-Apr-2009	29-Apr-2029
15.	Cardioxane	Ecuador	01	Registered		19-Apr-1993	1-656-1996	25-Sep-1996	25-Sep-2026
16.	Cardioxane	Ecuador	05	Registered		26-Mar-1993	1-715-1995	17-Feb-1995	17-Feb-2025
17.	Cardioxane	El Salvador	05	Registered			186/92	07-Jun-1999	07-Jun-2029

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed' -- Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
18.	Cardioxane	Estonia	05	Registered	9305193	08-Jun-1993	09197	14-Mar-1994	22-Apr-2031
19.	Cardioxane	EU	05	Registered	006441737	07-Nov-2007	006441737	17-Oct-2008	07-Nov-2027
20.	Cardioxane	Greece	05	Registered	F148560	21-Feb-2003	F148560	19-Jul-2004	21-Feb-2033
21.	Cardioxane	Guatemala	05	Registered			78041	07-May-1996	06-May-2026
22.	Cardioxane	Hong Kong	05	Registered		07-Jan-2003	200309549	29-Jul-2003	06-Jan-2030
23.	佳定善	Hong Kong	05	Registered	200309549	01-Apr-2003	200314629	03-Dec-2003	31-Mar-2030

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
24.	Cardioxane	India	05	Registered	1237904	18-Sep-2003	1237904	18-Sep-2005	18-Sep-2023
25.	Cardioxane	Ireland	05	Registered	1997/04236	17-Nov-1997	266284	17-Nov-1997	17-Nov-2027
26.	Cardioxane	Israel	05	Registered	114816	15-Sep-1997	114816	07-Jan-1999	15-Sep-2028
27.	Cardioxane	Japan	05	Registered	2002044972	30-May-2002	0004717394	10-Oct-2003	10-Oct-2023
28.	Cardioxane	Kosovo	05	Registered		24-Jun-2008	3161	04-Jul-2011	24-Jun-2028
29.	Cardioxane	Kyrgyzstan	05	Registered		06-May-2010	10576	29-Apr-2011	06-May-2030

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
30.	Cardioxane	Latvia	05	Registered	M-93-1316	01-Feb-1993	M15000	20-May-1994	01-Feb-2033
31.	Cardioxane	Lebanon	05	Registered			87391	23-May-2001	23-May-2031
32.	Cardioxane	Lithuania	05	Registered	RL 4224	13-Feb-1993	8322	05-Oct-1993	13-Feb-2033
33.	Cardioxane	Macau	05	Registered		25-Jul-2005	N/17980	09-Nov-2005	09-Nov-2026
34.	Cardioxane	Macau	05	Registered		25-Jul-2005	N/17979	09-Nov-2005	09-Nov-2026
35.	Cardioxane	Malta	05	Registered	42601	31-Aug-2004	42601	18-Nov-2004	31-Aug-2024

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
36.	Cardioxane	Mexico	05	Registered	0173059	15-Jul-1993	477119	14-Oct-1994	15-Jul-2023
37.	Cardioxane & Heart Logo	Mexico	05	Registered	0370860	12-Apr-1999	960012	22-Sep-2005	12-Apr-2029
38.	Cardioxane	Moldova	05	Registered		16-Sep-2003	R11282	05-Oct-2004	16-Sep-2023
39.	Cardioxane	Montenegro	05	Registered		24-Sep-1990	3238PP	27-Feb-1995	24-Sep-2030
40.	Cardioxane	New Zealand	05	Registered	284035	29-Oct-1997	284035	17-Jun-1998	29-Oct-2024
41.	Cardioxane	Nicaragua	05	Registered			26341	08-Mar-2017	04-Aug-2024

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed' -- Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
42.	Cardioxane	North Macedonia	05	Registered	199491898	09-May-1994	1425	24-Nov-1995	24-Sep-2030
43.	Cardioxane	Norway	05	Registered	19883782111	22-Aug-1988	140357	07-Feb-1990	07-Feb-2030
44.	Cardioxane (Chinese characters)	P.R. China	05	Registered		01-Apr-2003	3508722	14-Jan-2005	13-Jan-2025
45.	Cardioxane	Panama	05	Registered	68608	19-Nov-1993	68608	23-Jun-1995	23-Jun-2025
46.	Cardioxane	Paraguay	05	Registered	56636/2013	17-Mar-1993	56636/2013	02-Dec-2003	02-Dec-2023
47.	Cardioxane	Paraguay	01	Registered	44579/2013	19-Mar-1993	44579/2013	16-Oct-2003	16-Oct-2023

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed' -- Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
48.	Cardioxane	Peru	05	Registered	218420-1993	19-Mar-1993	P00007190	16-Mar-1994	16-Mar-2024
49.	Cardioxane	Portugal	05	Registered	250088	20-Sep-1988	250088	29-May-1992	20-Aug-2028
50.	Cardioxane	Republic of Korea	05	Registered	40-0420663	12-Sep-1997	40-0420663	10-Sep-1998	10-Sep-2028
51.	Cardioxane (Korean)	Republic of Korea	05	Registered	40-0831359	07-Aug-2009	40-0831359	29-Jul-2010	29-Jul-2030
52.	Cardioxane	Russia	05	Registered	134951	22-Apr-1991	100869	13-Dec-1991	22-Apr-2031
53.	Cardioxane	Serbia	05	Registered	199001709	24-Sep-1990	36320	11-Nov-1991	24-Sep-2030

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
54.	Cardioxane	Singapore	05	Registered		07-Jan-2003	T03/00131B	12-Jun-2003	07-Jan-2033
55.	佳定善	Singapore	05	Registered		13-Jun-2005	T05/10063 Fese Character	21-Feb-2006	13-Jun-2025
56.	Cardioxane	South Africa	05	Registered		15-Sep-1997	97/14011	15-Sep-1997	15-Sep-2027
57.	Cardioxane	Switzerland	05	Registered	05978/1988	23-Aug-1988	366285	08-Feb-1989	23-Aug-2028
58.	佳定善	Taiwan	05	Registered		02-Apr-2003	1074054	01-Dec-2003	30-Nov-2023
59.	Cardioxane	Tajikistan	05	Registered		22-Jan-2003	5908	01-Apr-2004	22-Jan-2033

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
60.	Cardioxane	Thailand	05	Registered		09-Dec-1997	Kor80072	16-Oct-1998	08-Dec-2027
61.	Cardioxane	Thailand	05	Registered		15-Feb-2000	Kor130564	08-Mar-2001	14-Feb-2030
62.	Cardioxane	Turkey	05	Registered	90-007271	11-Sep-1990	123532	25-Feb-1991	11-Sep-2030
63.	Cardioxane	Ukraine	05	Registered		26-Nov-1997	20614	17-Sep-2001	26-Nov-2027
64.	Cardioxane	United Kingdom	05	Registered	UK00906441737	07-Nov-2007	UK00906441737	17-Oct-2008	07-Nov-2027
65.	Cardioxane	Uruguay	05	Registered	391190	12-Apr-1993	391190	26-May-1998	26-May-2028

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed' -- Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Expiry Date
66.	Cardioxane	Uzbekistan	05	Registered		05-Dec-1997	8318	01-Mar-1999	05-Dec-2027

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

Part 2 SAVENE

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
1.	Savene	Australia	05	Registered	858935	24-Aug-2005	858935	24-Aug-2005	24-Aug-2025
2.	Savene	EU	01, 05, 10	Registered		24-Feb-2005	004319414	13-Nov-2007	24-Feb-2025
3.	Savene	Hong Kong	05	Registered		03-May-2007	300863613	25-Mar-2008	02-May-2027
4.	Savene	India	05	Registered	1383233	08-Sep-2005	1383233	22-Jul-2008	08-Sep-2025
5.	Savene	Indonesia	05	Registered	D002007014390	09-May-2007	IDM060183787	06-Nov-2008	09-May-2027
6.	Savene	International	05	Registered	858935	24-Aug-2005	858935	24-Aug-2005	24-Aug-2025

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
7.	Savene	Israel	05	Registered	199835	01-May-2007	199835	03-Sep-2008	01-May-2027
8.	Savene	Malaysia	05	Registered	07007736	03-May-2007	07007736	27-Apr-2012	03-May-2027
9.	Savene	Mexico	05	Registered	1600154	30-Sep-2015	1600154	16-Dec-2015	30-Sep-2025
10.	Savene	Mexico	05	Registered	930150	14-Sep-2005	930150	24-Apr-2006	14-Sep-2025
11.	Savene	New Zealand	05	Registered	735355	08-Sep-2005	735355	09-Mar-2006	08-Sep-2025
12.	Savene	Norway	05	Registered	858935	24-Aug-2005	858935	24-Aug-2005	24-Aug-2025

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed' -- Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
13.	Savene	P.R. China	05	Registered		24-Aug-2005	858935	24-Aug-2005	
14.	Savene	Russia	05	Registered		24-Aug-2005	858935	24-Aug-2005	
15.	Savene	Saudi Arabia	05	Registered		25-Sep-2007	1142/11	21-Feb-2010	13-Feb-2027
16.	Savene	Singapore	05	Registered		24-Aug-2005	858935	24-Aug-2005	
17.	Savene	Switzerland	05	Registered		24-Aug-2005	858935	24-Aug-2005	
18.	Savene	Taiwan	05	Registered		04-May-2007	1292064	16-Dec-2007	15-Dec-2027

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
19.	Savene	Thailand	05	Registered		18-May-2007	Kor282566	07-Jul-2008	17-May-2027
20.	Savene	Turkey	05	Registered		24-Aug-2005	858935	24-Aug-2005	
21.	Savene	United Kingdom	01, 05, 10	Registered	UK00904319414	24-Feb-2005	UK00904319414	13-Nov-2007	24-Feb-2025
22.	Savene	Vietnam	05	Registered		24-Aug-2005	858935	24-Aug-2005	

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

Part 3 TOTECT

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
1.	Totect	Canada	05	Registered	1275533-00	13-Oct-2005	TMA872299	28-Feb-2014	28-Feb-2029
2.	Totect	United States	05	Registered	78732996	13-Oct-2005	3399644	18-Mar-2008	18-Mar-2028

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed -- Clinigen Limited / CNX Therapeutics Limited]

Part 4 ETHYOL

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
1.	Ethyol	African Intellectual Property Organisation	05	Registered		23-Jul-1996	36569	23-Jul-1996	23-Jul-2026
2.	Ethyol	Australia	05	Registered	631614	06-Jun-1994	631614	03-Jul-1996	06-Jun-2024
3.	Ethyol	Austria	05	Registered		13-Apr-1989	126675	13-Apr-1989	13-Apr-2029
4.	Ethyol	Benelux	05	Registered	722987	15-Dec-1988	452805	01-Jun-1989	15-Dec-2028
5.	Ethyol	Brazil	05	Registered	816824690	10-Aug-1992	816824690	20-Nov-1993	30-Nov-2023
6.	Ethyol Logo	Brazil	05	Registered	824513720	24-Apr-2002	824513720	24-Apr-2007	24-Apr-2027

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed' -- Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
7.	Ethyol Logo	Canada	05	Registered	1134657	19-Mar-2002	TMA590642	24-Sep-2003	24-Sep-2033
8.	Ethyol	Chile	05	Registered	793038	06-Sep-1994	813609	03-Nov-1997	03-Nov-2027
9.	Ethyol	El Salvador	05	Registered		19-Jun-1990	236/28/473	15-Nov-1995	15-Nov-2025
10.	Ethyol	EU	05	Registered	000185520	01-Apr-1996	000185520	18-Nov-1998	01-Apr-2026
11.	Ethyol Logo	EU	05	Registered	002615102	14-Mar-2002	002615102	16-Jan-2007	14-Mar-2032
12.	Ethyol	France	05	Registered	1539196	14-Dec-1988	1539196	14-Dec-1988	14-Dec-2028

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
13.	Ethyol	Hong Kong	05	Registered		04-Jul-1992	199401791	04-Jul-1992	03-Jul-2023
14.	Ethyol (Logo)	Hong Kong	05	Registered		16-Mar-2002	200212460	16-Mar-2002	16-Mar-2029
15.	Ethyol	Iceland	05	Registered	514/1993	24-Jun-1993	938/1993	28-Dec-1993	28-Dec-2023
16.	Ethyol	Ireland	05	Registered	1988/05630	16-Dec-1988	128982	16-Dec-1988	15-Dec-2029
17.	Ethyol	Italy	05	Registered	0001304831	30-Dec-2008	1304831	07-Jun-2010	03-Jan-2029
18.	Ethyol	Japan	05	Registered	1993039589	20-Apr-1993	3159301	31-May-1996	31-May-2026

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
19.	ETHYOL (in Katakana)	Japan	05	Registered	1997170673	27-Oct-1997	4231148	14-Jan-1999	14-Jan-2029
20.	Ethyol	Liechtenstein	05	Registered	1993-444	22-Jul-1993	8808	12-Dec-1997	22-Jul-2023
21.	Ethyol	Malaysia	05	Registered	92004663	07-Jul-1992	92004663	07-Jul-1992	07-Jul-2029
22.	Ethyol	Malawi	05	Registered	268/96	30-May-1996	268/96	30-May-1996	30-May-2031
23.	Ethyol Logo	New Zealand	05	Registered	654021	15-Mar-2002	654021	19-Sep-2002	15-Mar-2029
24.	Ethyol	Norway	05	Registered	19885731	15-Dec-1988	140269	25-Jan-1990	25-Jan-2030

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
25.	Ethyol in Chinese characters 佳定善	P.R. China	05	Registered		09-Oct-1998	1360850	07-Feb-2000	06-Feb-2030
26.	Ethyol	P.R. China	05	Registered		09-May-1996	1074828	14-Aug-1997	13-Aug-2027
27.	Ethyol	Panama	05	Registered		05-Jan-1994	69144	29-Jun-1995	29-Jun-2025
28.	Ethyol	Russia	05	Registered	95710055	08-Sep-1995	149406	15-Jan-1997	08-Sep-2025
29.	Ethyol	Switzerland	01, 05	Registered	07886/1994	09-Nov-1994	423918	09-Nov-2004	09-Nov-2024
30.	Ethyol	Switzerland	05	Registered	02715/1989	07-Apr-1989	371850	07-Apr-1989	07-Apr-2029

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed -- Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewal Date
31.	Ethyol Logo	Switzerland	05	Registered	02343/2002	14-Mar-2002	500032	13-Jun-2002	14-Mar-2032
32.	Ethyol	Tunisia	05	Registered		03-Jul-1996	TN/E/1996/801	03-Jul-1996	03-Jul-2031
33.	Ethyol	Turkey	05	Registered	95-002177	15-Mar-1995	158113	26-Jun-1995	15-Mar-2025
34.	Ethyol Logo	Turkey	05	Registered	2002-06179	25-Mar-2002	2002.06179	23-Nov-2004	25-Mar-2032
35.	Ethyol	United Kingdom	05	Registered	UK00900185520	01-Apr-1996	UK00900185520	18-Nov-1998	01-Apr-2026
36.	Ethyol Logo	United Kingdom	05	Registered	UK00902615102	14-Mar-2002	UK00902615102	16-Jan-2007	14-Mar-2032

[Catalyst - Schedule to IPR Assignment and DN Transfer Deed - Clinigen Limited / CNX Therapeutics Limited]

No.	Mark	Territory	Class	Legal Status	Application Number	Application Date	Registration Number	Registration Date	Renewed Date
37.	Ethyol	United States	05	Registered	73751893	14-Sep-1988	1618361	23-Oct-1990	23-Oct-2030

[Catalyst -- Schedule to IPR Assignment and DN Transfer Deed -- Clinigen Limited / CNX Therapeutics Limited]

EXECUTED as a deed by **CLINIGEN LIMITED**,
acting by Richard Paling, a director,
in the presence of:

} DocuSigned by:
Richard Paling
2187A10F15914B1...
Director


Witness's Signature Richard Adair
1D6BF6A26102452...


Name: Richard Adair

Address: Idis House, Chrchfield Road, Weybridge, Surrey, KT13 8DB

Occupation: Head of Legal

EXECUTED as a deed by **CNX THERAPEUTICS LIMITED**, acting by Guy Clark, a director, in the presence of:

} 
Director

Witness's Signature 
Name: Renatta Tomkinson
Address: 11 Tissimans Court, Basbow Lane, Bishops Stortford, CM23 2TW
Occupation: Solicitor